金纳多注射液联合地塞米松治疗突发性耳聋的效果及对血清ET、sVCAM-1、AECA水平的影响

摘要
图/表
参考文献(26)
相关文章 (15)

全文: PDF (571 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究金纳多注射液联合地塞米松治疗突发性耳聋的效果及对血清内皮素（ET）、可溶性血管细胞间黏附因子-1（sVCAM-1）及抗内皮细胞抗体（AECA）水平的影响。方法选择2018年6月至2021年4月江苏省常州市妇幼保健院接诊的106例突发性耳聋患者作为研究对象，按照随机数字表法将其分为研究组和对照组，每组53例。对照组在常规治疗基础上给予地塞米松治疗，研究组在对照组基础上联合金纳多注射液治疗，两组维持给药1周。分别采用放射免疫法检测血清ET水平，双抗体夹心双抗体夹心酶联免疫吸附试验检测患者治疗前及治疗后3 d的血清sVCAM-1及AECA水平，并比较两组患者的临床疗效、症状改善时间及药物不良反应等情况。结果治疗过程中，对照组有2例中途退出，最终对照组纳入51例，研究组纳入53例。治疗后，两组血清ET、sVCAM-1及AECA表达水平较治疗前均降低，且研究组均低于对照组，差异有统计学意义（P ＜ 0.05）。研究组临床疗效优于对照组，差异有统计学意义（P ＜ 0.05）。研究组症状改善时间短于对照组，差异有统计学意义（P ＜ 0.05）。两组总不良反应发生率比较，差异无统计学意义（P ＞ 0.05）。结论给予突发性耳聋患者金纳多注射液联合地塞米松治疗，可缩短患者的症状改善时间，有效降低患者血清ET、sVCAM-1及AECA表达水平，临床疗效较佳且安全性良好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱丽平1 谭晓晔2▲ 蒯烨滨1 邵炳焕1

关键词 ：金纳多注射液, 地塞米松, 突发性耳聋, 临床疗效, 血清内皮素, 血清可溶性血管细胞间黏附因子-1, 血清抗内皮细胞抗体

Abstract：Objective To investigate the curative effect of Gennadol Injection combined with Dexamethasone in the treatment of sudden deafness and the effects on serum endothelin (ET), soluble vasccular cell adhesion molecule 1 (sVCAM-1) and anti-endothelial cell antibody (AECA). Methods A total of 106 patients with sudden deafness admitted to Changzhou Maternal and Child Health Hospital of Jiangsu Province from June 2018 to April 2021 were selected as the research subjects, and they were divided into study group and control group according to random number table method, with 53 patients in each group. The control group was given Dexamethasone on the basis of conventional treatment, while the research group was given Nandol Injection on the basis of the control group. Both groups maintained administration for one week. Serum ET levels were detected by radioimmunoassay, serum sVCAM-1 and AECA levels were detected by double-antibody sandwich enzyme-linked immunosorbent assay before and three days after treatment, and clinical efficacy, symptom improvement time, and adverse drug reactions were compared between the two groups. Results During the treatment, two cases in the control group dropped out, and finally 51 cases in the control group and 53 cases in the study group were included. After treatment, the expression levels of ET, sVCAM-1, and AECA in serum of two groups were lower than before treatment, and the study group was lower than the control group, the differences were statistically significant (P ＜ 0.05). The clinical efficacy of the study group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05). The symptom improvement time of the study group was shorter than that of the control group, and the difference was statistically significant (P ＜ 0.05). There was no significant difference in the incidence of total adverse reactions between the two groups (P ＞ 0.05). Conclusion Treatment of patients with sudden deafness with Gennadol Injection combined with Dexamethasone can shorten the symptom improvement time of patients, effectively reduce the expression levels of ET, sVCAM-1, and AECA in serum of patients, with good clinical efficacy and safety.

Key words： Genadol Injection Dexamethasone Sudden deafness Clinical efficacy Serum endothelin Serum soluble vascular intercellular adhesion factor-1 Serum anti-endothelial cell antibody

基金资助:江苏省重点研发计划专项资金项目（BE2018703）。

通讯作者: ▲通讯作者

作者简介: 朱丽平（1988.11-），女，硕士；研究方向：过敏性鼻炎。

引用本文:

朱丽平1 谭晓晔2▲ 蒯烨滨1 邵炳焕1. 金纳多注射液联合地塞米松治疗突发性耳聋的效果及对血清ET、sVCAM-1、AECA水平的影响[J]. 中国医药导报, 2022, 19(6): 106-109.
ZHU Liping1 TAN Xiaoye2▲ KUAI Yebin1 SHAO Binghuan1. Effect of Gennadol Injection combined with Dexamethasone in the treatment of sudden deafness and its effect on serum ET, sVCAM-1 and AECA levels#br#. 中国医药导报, 2022, 19(6): 106-109.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I6/106

[1] Chandrasekhar SS，Tsai DB，Schwartz SR，et al. Clinical Practice Guideline：Sudden Hearing Loss（Update）[J]. Otolaryngol Head Neck Surg，2019，161（7）：S1-S45.
[2] Herrera M，Garcia BJ，Garcia AA，et al. Update on consensus on diagnosis and treatment of idiopathic sudden sensorineural hearing loss [J]. Acta Otorrinolaringol Esp（Engl Ed），2019，70（5）：290-300.
[3] 石琰，薛茜，刘美畅.天麻素注射液联合地塞米松治疗突发性耳聋的疗效及对患者血液流变学和听力值的影响[J].中国基层医药，2021，28（4）：558-562.
[4] 张淑娟，李霞，曹莎，等.腺苷钴胺联合地塞米松治疗对突发性耳聋患者的临床疗效[J].国际医药卫生导报，2020，26（17）：2613-2615.
[5] 谌祎玮，周建波，谢昀，等.银杏达莫注射液联合地塞米松治疗突发性耳聋的疗效及对血清sVCAM-1、CGRP水平的影响[J].现代生物医学进展，2019，19（23）：4565-4568.
[6] 朱丽娜.鼓室注射地塞米松治疗糖尿病伴突发性耳聋的临床分析[J].北方药学，2017，14（5）：66-67.
[7] 刘亚楠，张春和，王敬敬，等.突发性耳聋患者血清CysC、ET-1表达与血流动力学及听力预后的相关性研究[J].标记免疫分析与临床，2020，27（11）：1911-1914，1969.
[8] 李利红，张卫杰.金纳多辅助治疗突发性耳聋的可行性及对患者血流动力学和血管内皮功能的影响[J].包头医学院学报，2019，35（12）：26-27.
[9] 中华耳鼻咽喉头颈外科杂志编辑委员会，中华医学会耳鼻咽喉头颈外科学分会.突发性聋诊断和治疗指南（2015）[J].中华耳鼻咽喉头颈外科杂志，2015，50（6）：443-447.
[10] 孙海敏，张静，王宁宁，等.GM1注射液联合高压氧治疗突发性耳聋的疗效及机制分析[J].中华航海医学与高气压医学杂志，2020，27（6）：713-717.
[11] 王明明，王英俊，胡娜，等.突发性聋患者3D-FLAIR MRI表现与其临床特征及疗效预后的相关性分析[J].中华耳鼻咽喉头颈外科杂志，2021，56（5）：424-430.
[12] Akil F，Yollu U，Yilmaz M，et al. Simultaneous idiopathic bilateral sudden hearing loss-characteristics and response to treatment [J]. Braz J Otorhinolaryngol，2017，12（3）：137-139.
[13] 杨竹梅，谢书华，张雨帆.银杏叶提取物对突发性耳聋患者血液流变学及血清凝血酶时间血小板因子凝血酶原时间的影响[J].山西医药杂志，2021，50（9）：1536-1538.
[14] 刘顺杰.地塞米松治疗突发性耳聋临床疗效观察[J].深圳中西医结合杂志，2017，27（17）：170-171.
[15] 胡海艳，施丽琴.高压氧联合地塞米松治疗突发性耳聋的疗效及相关影响因素分析[J].天津医药，2018，46（3）：264-268.
[16] 刘春玲，张少燕，梁久平，等.金纳多联合巴曲酶治疗突发性耳聋疗效及对血液流变学与内皮功能影响[J].临床军医杂志，2018，46（4）：476-477，480.
[17] Nishad RK，Jain AK，Singh M，et al. Randomised Controlled Clinical Study of Injection Caroverine and Ginkgo Biloba Extract in Cochlear Synaptic Tinnitus [J]. Indian J Otolaryngol Head Neck Surg，2019，71（2）：1523-1528.
[18] Mehta N，Mehta S. Comparative Evaluation of Injection Dexamethasone and Oral Glycerol Versus Injection Dexamethasone Alone in the Treatment of Sudden Onset Sensorineural Deafness [J]. Ear Nose Throat J，2021，100（3）：317S-324S.
[19] Laccourreye O，Werner A，Laccourreye L，et al. Benefits，pitfalls and risks of phytotherapy in clinical practice in otorhinolaryngology [J]. Eur Ann Otorhinolaryngol Head Neck Dis，2017，134（2）：95-99.
[20] Kaur S，Sharma N，Nehru B. Anti-inflammatory effects of Ginkgo biloba extract against trimethyltin-induced hippocampal neuronal injury [J]. Inflammopharmacology，2018， 26（1）：87-104.
[21] 高占梅，宋扬，刘华，等.甲泼尼龙与地塞米松治疗突发性耳聋疗效比较的Meta分析[J].首都医科大学学报，2018，39（2）：265-271.
[22] 刘小晶，文凤妮，唐利衡.地塞米松联合巴曲酶治疗突发性耳聋的临床观察[J].锦州医科大学学报，2018，39（3）：59-61.
[23] 朱雅静，刘映岐，王天宇，等.鼓室内注射地塞米松联合静脉注射用药与其他治疗方法对突发性感音神经性聋患者疗效的回顾性研究[J].中国医药科学，2020，10（13）：6-10，19.
[24] Chang WT，Zee B，Lee H，et al. Dexamethasone eardrop with grommet placement vs intratympanic steroid injection for sudden sensorineural hearing loss：A randomized prospective clinical trial [J]. Am J Otolaryngol，2020，41（4）：102-104.
[25] Hobson CE，Alexander TH，Harris JP. Primary treatment of idiopathic sudden sensorineural hearing loss with intratympanic dexamethasone [J]. Curr Opin Otolaryngol Head Neck Surg，2016，24（5）：407-412.
[26] 张福宏，陈小婉，仇志强.地塞米松、金纳多联合高压氧综合治疗特发性突聋临床观察[J].实用中西医结合临床，2018，18（4）：64-66.